AI Article Synopsis
- There's an urgent need to boost the effectiveness of seasonal influenza vaccines, with recombinant hemagglutinin showing potential benefits over traditional methods.
- In a study, two adjuvants (Advax-CpG55.2 and alum-CpG55.2) were tested to see if they could improve the immune response of a quadrivalent influenza vaccine (QIV) in mice.
- Results showed that the adjuvanted vaccines led to much higher levels of protective antibodies and significantly reduced illness in mice infected with the H1N1 strain, suggesting that this approach could be a better alternative for seasonal flu vaccinations.
Article Abstract
There is a need to improve the effectiveness of seasonal influenza vaccines. Influenza vaccines based on recombinant hemagglutinin offer advantages over traditional approaches. We asked whether Advax-CpG55.2 or alum-CpG55.2 adjuvants could enhance the immunogenicity of a quadrivalent influenza vaccine (QIV) comprising recombinant full-length native hemagglutinins (HA0) produced in Sf9 insect cells. Adult C57BL/6 mice were immunized intramuscularly twice 10 days apart with 4 μg of QIV alone or with adjuvant. QIV induced only modest levels of anti-influenza IgG1 whereas the adjuvanted formulations induced significantly higher levels of IgG1 plus IgG2c. When challenged with the H1N1pdm strain, A/South Australia/348/2023, adjuvanted QIV immunized mice showed minimal illness, whereas QIV alone immunized mice all succumbed to infection. Advax-CpG55.2 adjuvanted QIV similarly increased influenza-specific IgG against all four vaccine strains in Cynomolgus macaques. Adjuvanted recombinant hemagglutinin approaches offer a promising alternative to existing seasonal influenza vaccine platforms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2025.126707 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunogenicity in mice and non-human primates of an Advax-CpG55.2-adjuvanted recombinant hemagglutinin seasonal quadrivalent influenza vaccine.
Vaccine
January 2025
Vaxine Pty Ltd, Warradale, Adelaide, SA 5046, Australia; Australian Respiratory and Sleep Medicine Institute Ltd, Adelaide, SA 5042, Australia. Electronic address:
Article Synopsis
- There's an urgent need to boost the effectiveness of seasonal influenza vaccines, with recombinant hemagglutinin showing potential benefits over traditional methods.
- In a study, two adjuvants (Advax-CpG55.2 and alum-CpG55.2) were tested to see if they could improve the immune response of a quadrivalent influenza vaccine (QIV) in mice.
- Results showed that the adjuvanted vaccines led to much higher levels of protective antibodies and significantly reduced illness in mice infected with the H1N1 strain, suggesting that this approach could be a better alternative for seasonal flu vaccinations.
Combination Adjuvants Enhance Recombinant H5 Hemagglutinin Vaccine Protection Against High-Dose Viral Challenge in Chickens.
Vaccines (Basel)
December 2024
College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
Background: Recombinant avian influenza subunit vaccines often require adjuvants to enhance immune responses. This study aims to evaluate the immune-enhancing potential of seven combination adjuvants in specific pathogen-free (SPF) chickens.
Methods: SPF chickens were vaccinated with combinations of ISA78VG and adjuvants, including Quil-A, CpG, and monophosphoryl lipid A (MPLA).
Computationally Optimized Hemagglutinin Proteins Adjuvanted with Infectimune Generate Broadly Protective Antibody Responses in Mice and Ferrets.
Vaccines (Basel)
December 2024
Center for Vaccines and Immunology, University of Georgia, Athens, GA 30605, USA.
Standard-of-care influenza vaccines contain antigens that are typically derived from components of wild type (WT) influenza viruses. Often, these antigens elicit strain-specific immune responses and are susceptible to mismatch in seasons where antigenic drift is prevalent. Thanks to advances in viral surveillance and sequencing, influenza vaccine antigens can now be optimized using computationally derived methodologies and algorithms to enhance their immunogenicity.
View Article and Find Full Text PDFDirected Mutagenesis for Arginine Substitution of a Recombinant Lectin Disrupts Its Cytotoxic Activity.
Int J Mol Sci
December 2024
Facultad de Ciencias Naturales, Universidad Autónoma de Querétaro, Querétaro 76230, Querétaro, Mexico.
Recently, we reported that a recombinant Tepary bean () lectin (rTBL-1) induces apoptosis in colon cancer cell lines and that cytotoxicity was related to differential recognition of β1-6 branched -glycans. Sequencing analysis and resolution of the rTBL-1 3D structure suggest that glycan specificity could be strongly influenced by two arginine residues, R103 and R130, located in the carbohydrate binding pocket. The aim of this work was to determine the contribution of these residues towards cytotoxic activity.
View Article and Find Full Text PDFComparison of neuraminidase inhibiting antibody responses elicited by egg- and cell-derived influenza vaccines.
Vaccine
January 2025
Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA. Electronic address:
Unlabelled: Neuraminidase (NA)-specific antibodies contribute to immunity against influenza. While studies have demonstrated increased NA inhibiting (NAI) antibody titers after vaccination with egg-derived inactivated influenza vaccines (eIIV), the response to cell culture-derived (c) IIV has not been reported.
Methods: An immunogenicity sub-study was performed within a clinical trial comparing the effectiveness of egg, cell, and recombinant hemagglutinin (HA)-derived influenza vaccines during the 2018-2019 and 2019-2020 influenza seasons.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!